[1] |
Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies[J]. Int J Dermatol, 2018,doi: 10.1111/ijd.14246.
|
[2] |
Kamata M, Tada Y. Safety of biologics in psoriasis[J]. J Dermatol, 2018,45:279⁃286. doi: 10.1111/1346⁃8138.14096.
|
[3] |
Cannizzaro MV, Franceschini C, Esposito M, et al. Hepatitis B reactivation in psoriasis patients treated with anti⁃TNF agents: prevention and management[J]. Psoriasis (Auckl), 2017,7(1):35⁃40. doi: 10.2147/PTT.S108209.
|
[4] |
Fabbrocini G, Napolitano M, Megna M, et al. Treatment of atopic dermatitis with biologic drugs[J]. Dermatol Ther (Heidelb), 2018,8(4):527⁃538. doi: 10.1007/s13555⁃018⁃0258⁃x.
|
[5] |
Kocatürk E, Zuberbier T. New biologics in the treatment of urticaria[J]. Curr Opin Allergy Clin Immunol, 2018,18(5):425⁃431. doi:10.1097/ACI.0000000000000466.
|
[6] |
Robinson JV, James AL. Some observations on the effects produced in white mice following the injection of certain suspensions of corroding bacilli[J]. Br J Exp Pathol, 1975,56(1):14⁃16.
|
[7] |
Kluger HM, Chiang V, Mahajan A, et al. Long⁃term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase ii trial[J]. J Clin Oncol, 2019,37(1):52⁃60. doi: 10.1200/JCO.18.00204.
|
[8] |
Fathi R, Armstrong AW. The role of biologic therapies in dermatology[J]. Med Clin North Am, 2015,99(6):1183⁃1194. doi: 10.1016/j.mcna.2015.07.008.
|
[9] |
李峰, 晋红中. 119例英夫利西单抗不良反应的文献分析[J]. 中国药物警戒, 2016,13(4):229⁃232.
|
[10] |
代菲, 储文功. 70例阿达木单抗注射液的药物不良反应报告分析[J]. 中国新药杂志, 2013(7):853⁃856.
|
[11] |
张瑞丽, 朱小红, 华海康, 等. 阿达木单抗治疗重度银屑病14例临床疗效及安全性观察[J]. 中华皮肤科杂志, 2018,51(8):604⁃606. doi: 10.3760/cma.j.issn.0412⁃4030.2018.08.012.
|
[12] |
Cui L, Chen R, Subedi S, et al. Efficacy and safety of biologics targeting IL⁃17 and IL⁃23 in the treatment of moderate⁃to⁃severe plaque psoriasis: a systematic review and meta⁃analysis of randomized controlled trials[J]. Int Immunopharmacol, 2018,62:46⁃58. doi: 10.1016/j.intimp.2018.06.020.
|
[13] |
Fu M, Wang G. Biologic treatments for psoriasis in China: current status and potential tuberculosis and hepatitis B virus risks[J]. Int J Dermatol Venereol, 2018,1(2):99⁃106.
|
[14] |
Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate⁃to⁃severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)[J]. J Eur Acad Dermatol Venereol, 2018,32(9):1507⁃1514. doi:10.1111/jdv. 14878.
|
[15] |
Tonacci A, Billeci L, Pioggia G, et al. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature[J]. Pharmacotherapy, 2017,37(4):464⁃480. doi: 10.1002/phar.1915.
|
[16] |
Ariëns LFM, Bakker DS, van der Schaft J, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy[J]. Ther Adv Chronic Dis, 2018,9(9):159⁃170. doi:10.1177/204062 2318773686.
|
[17] |
Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases[J]. Annu Rev Med, 2004,55:477⁃503. doi: 10.1146/annurev.med.55.091902.10 4249.
|
[18] |
朱昆, 于倩, 郭义明, 等. 再次输注利妥昔单抗致严重不良反应1例[J]. 武警医学, 2018, 29(11):1091⁃1093.
|
[19] |
梁佳. 利妥昔单抗致心律失常1例[J]. 医药导报, 2016,35(8):900⁃900. doi: 10.3870/j.issn.1004⁃0781.2016.08.024.
|
[20] |
杨勇, 罗宸婧, 杨阳. 利妥昔单抗注射液致间质性肺疾病合并呼吸衰竭案例分析[J]. 中国医药, 2017,12(8):1161⁃1163. doi: 10.3760/cma.j.issn.1673⁃4777.2017.08.011.
|
[21] |
李文静, 王志伟, 赵田华, 等. 小剂量利妥昔单抗治疗免疫性血小板减少症临床效果观察[J]. 解放军医药杂志, 2018,30(9):80⁃83. doi: 10.3969/j.issn.2095⁃140X.2018.09.022.
|
[22] |
Pottinger E, Woolf RT, Exton LS, et al. Exposure to biological therapies during conception and pregnancy: a systematic review[J]. Br J Dermatol, 2018,178(1):95⁃102. doi: 10.1111/bjd.15802.
|
[23] |
Dogra S, Mahajan R. Biologics in pediatric psoriasis⁃efficacy and safety[J]. Expert Opin Drug Saf, 2018,17(1):9⁃16. doi: 10.1080/14740338.2018.1391787.
|
[24] |
IMGJ B, MMB S, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis[J]. JAMA Dermatol, 2017,153(11):1147⁃1157. doi: 10.1001/jamadermatol.2017.3029.
|
[25] |
Wong PKK, Bagga H, Barrett C, et al. A practical approach to the use of conventional synthetic, biologic and targeted synthetic disease modifying anti⁃rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy[J]. Curr Rheumatol Rep, 2018,20(10):64. doi: 10.1007/s11926⁃018⁃0774⁃9.
|